All In MedTech

Device Trial Radar · NCT01234480

Intended Use Study of the BD SurePath Plus™ Pap

Last checked: Nov 20, 2026Latest source record: May 16, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

5,859

Actual

Start

Sep 2010

Primary completion

Mar 2012

Study completion Aug 2012

Sponsor

Lead sponsor
Becton, Dickinson and CompanyPublic (BDX)
Sponsor type
Industry
First posted
Nov 4, 2010

More device trials from this sponsor

Design

Study type
Interventional
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Diagnostic
Who can join
Female only, from 18 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will provide data on the performance of the BD SurePath Plus™ Pap test for identifying high grade cervical disease. This study will be conducted with approximately 12,500 women undergoing routine cervical cancer screening, of whom women with abnormal cytology and/or positive HPV test will be selected to undergo colposcopy and biopsy/ECC. Subjects with abnormal cytology results with biopsy results of less than or equal to CIN1 or CIN2 untreated will be asked to return in 6-8 months for follow-up testing. Subjects may be asked to proceed to a longer-term follow-up study and undergo cytological evaluation annually for 3 years (separate study).

Conditions

  • Uterine Cervical Neoplasms
  • Uterine Cervical Cancer
  • Neoplasms, Squamous Cell
  • Neoplasms, Glandular and Epithelial
  • Neoplasms by Histologic Type
  • Neoplasms
  • Papilloma

Interventions

  • BD SurePath Plus Pap testDevice

    BD SurePath Plus Pap test

  • BD SurePath Pap testDevice

    BD SurePath Plus Pap test

  • colposcopy with biopsy/ECCProcedure

    Colposcopy with biopsy/ECC for subjects with 1)BD SurePath Pap NILM, but HPV positive, or 2) BD SurePath Plus Pap test result of ASC-US or higher 3)BD SurePath Pap ASC-US or higher

  • HPV DNA testDevice

    digene HC2 HPV DNA test

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sensitivity, Specificity, PPV, and NPV of BD SurePath Plus Pap Test for the Determination of Cervical Disease as Defined by CIN2 or HigherTime frame: 10 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seattle Women's: Health, Research, Gynecology

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.